Clinical trial
A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma
NCT00028717 is registered in ClinicalTrials.gov with Commissie Voor Klinisch Toegepast Onderzoek as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma
- Lead sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- February 28, 2001
- Completion date
- Not reported
- Enrollment
- 400 (estimated)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.